Xtracare Foaming Facial Cleanser
Triclosan
Rejoice International
Human Otc Drug
NDC 57337-036Xtracare Foaming Facial Cleanser also known as Triclosan is a human otc drug labeled by 'Rejoice International'. National Drug Code (NDC) number for Xtracare Foaming Facial Cleanser is 57337-036. This drug is available in dosage form of Gel. The names of the active, medicinal ingredients in Xtracare Foaming Facial Cleanser drug includes Triclosan - 1 mg/237mg . The currest status of Xtracare Foaming Facial Cleanser drug is Active.
Drug Information:
| Drug NDC: | 57337-036 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Xtracare Foaming Facial Cleanser |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Triclosan |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Rejoice International |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Gel |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | TRICLOSAN - 1 mg/237mg
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH NOT FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 26 Nov, 2013 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 23 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part333A |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Rejoice International
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UPC: | 0849607050007
|
| UPC stands for Universal Product Code. |
| UNII: | 4NM5039Y5X
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 57337-036-01 | 237 mg in 1 BOTTLE (57337-036-01) | 26 Nov, 2013 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Xtracare (oil-free) foaming facial cleanser medicated to kill problem-causing bacteria without overdrying compare to clean & clear® foaming facial cleanser 8 fl. oz. (237 ml) oil free foaming facial cleanser
Product Elements:
Xtracare foaming facial cleanser triclosan water sodium c14-16 olefin sulfonate cocamidopropyl betaine polyoxyl 40 castor oil dmdm hydantoin edetate disodium citric acid monohydrate methylparaben propylparaben fd&c yellow no. 5 d&c red no. 33 triclosan triclosan
Indications and Usage:
Use to help reduce bacteria on the skin
Warnings:
Warnings for external use only when using this product avoid contact with eyes. if eye contact occurs, immediately flush with water. stop use and ask a doctor if excessive skin irritation develops or condition worsens symptoms last more than 7 days or clear up and occur again within a few days
Dosage and Administration:
Directions mix in hands with water. work into a foamy later. smooth over face and neck. rinse thoroughly.
Package Label Principal Display Panel:
Label image